Non-Autoinflammatory diseases(n=1545) | Autoinflammatory diseases (n=117) | |
Age (years) | ||
Mean±SD | 54.7±17.5 | 38.7±20.5 |
<18 | 41/1545 (2.7) | 17/117 (14.5) |
18–54 | 700/1545 (45.3) | 74/117 (63.2) |
55–64 | 328/1545 (21.2) | 8/117 (6.8) |
65–74 | 260/1545 (16.8) | 9/117 (7.7) |
≥75 | 216/1545 (14.0) | 9/117 (7.7) |
Female gender | 1038/1545 (67.2) | 64/117 (54.7) |
Comorbidities | ||
Respiratory disease | 204/1543 (13.2) | 6/117 (5.1) |
Interstitial lung disease | 60/1543 (3.9) | 0/117 (0.0) |
COPD | 61/1543 (4.0) | 2/117 (1.7) |
Asthma | 95/1543 (6.2) | 4/117 (3.4) |
Cardiovascular disease | 177/1543 (11.5) | 11/117 (9.4) |
Coronary heart diseases | 146/1543 (9.5) | 9/117 (7.7) |
Stroke | 42/1543 (2.7) | 5/117 (4.3) |
Diabetes | 156/1543 (10.1) | 8/117 (6.8) |
BMI (kg/m²) | 26.0 (22.0 ; 29.0) | 23.0 (21.0 ; 26.0) |
<30 | 1054/1388 (75.9) | 98/111 (88.3) |
30–39.9 | 297/1388 (21.4) | 10/111 (9.0) |
≥40 | 37/1388 (2.7) | 3/111 (2.7) |
Hypertension | 361/1543 (23.4) | 12/117 (10.3) |
Cancer | 57/1543 (3.7) | 3/117 (2.6) |
Smoking | 139/1543 (9.0) | 8/117 (6.8) |
Chronic renal failure | 80/1543 (5.2) | 5/117 (4.3) |
Number comorbidities | ||
0 | 674/1543 (43.7) | 76/117 (65.0) |
1 | 466/1543 (30.2) | 26/117 (22.2) |
2 | 230/1543 (14.9) | 8/117 (6.8) |
3 | 103/1543 (6.7) | 4/117 (3.4) |
4 | 58/1543 (3.8) | 3/117 (2.6) |
>4 | 12/1543 (0.8) | 0/117 (0.0) |
Rheumatic or inflammatory Diseases treatments | ||
Corticosteroid | 460/1542 (29.8) | 20/117 (17.1) |
Systemic corticosteroid doses≥10 mg/day | 176/458 (38.4) | 6/20 (30.0) |
NSSAIDs | 147/1542 (9.5) | 2/117 (1.7) |
Colchicine | 10/1542 (0.6) | 72/117 (61.5) |
Hydroxychloroquine | 146/1542 (9.5) | 0/117 (0.0) |
Methotrexate | 553/1542 (35.9) | 13/117 (11.1) |
Leflunomide | 66/1542 (4.3) | 0/117 (0.0) |
Salazopyrine | 17/1542 (1.1) | 0/117 (0.0) |
Mycophenolate Mofetil /mycophenolic acid | 41/1542 (2.7) | 0/117 (0.0) |
Azathioprine | 18/1542 (1.2) | 4/117 (3.4) |
IgIV | 10/1542 (0.6) | 0/117 (0.0) |
Targeted biologic or synthetic therapies | ||
anti-TNF | 469/1542 (30.4) | 18/117 (15.4) |
anti-IL6R | 56/1542 (3.6) | 5/117 (4.3) |
anti-IL17A | 51/1542 (3.3) | 0/117 (0.0) |
anti-IL1 | 2/1542 (0.1) | 12/117 (10.3) |
abatacept | 34/1542 (2.2) | 1/117 (0.9) |
JAK inhibitor | 56/1542 (3.6) | 1/117 (0.9) |
Rituximab | 83/1542 (5.4) | 0/117 (0.0) |
Other biologics | 33/1542 (2.1) | 1/117 (0.9) |
Values are presented as no./total no. (%) unless otherwise indicated
COPD, Chronic obstructive pneumopathy disease; IgIV, Intravenous immunoglobulins.